The cholesterol controversy : the series by Cilia Vincenti, Albert
in the previous instalment we learnt how Ronald Krauss, one of the most respected nutrition researchers, had worked out that LDL-cholesterol consisted of two sub-fractions, one with 
large soft particles and the other with small dense particles, and 
that the small dense particle sub-fraction was the one linked to 
atherosclerosis and not the other. He also noted that saturated 
fats increased the “good” sub-fraction and lowered the “bad” 
sub-fraction, and that carbohydrates did the opposite. This 
suggested that carbohydrates were implicated in atherosclerosis 
rather than saturated fat.
Krauss did not push his LDL sub-fraction findings too 
hard with his colleagues, even after they had been confirmed 
by others,1 lest they might get very upset at the implication 
that they had been wrong about LDL-cholesterol all along.  
Indeed, most of his peers found it convenient to ignore his 
findings. However, in 1996 he managed to make the point in the 
American Heart Association’s (AHA) guidelines that saturated 
fatty acids in diary, meat and palm oil were different and did 
not have the same effect on blood lipids.2 It took another decade 
for other guidelines to incorporate these fine points about 
different saturated fats, and then only in France. The French 
2010 official dietary advice noted that only saturated fats found 
predominantly in palm and coconut oil could possibly be 
linked to atherosclerosis due to their effect on LDL-cholesterol, 
and that the saturated fat found in meat, dairy and eggs was 
completely exonerated.
In the end, however, Krauss lost the battle to traditionalists, 
and in 2006 the AHA guidelines swung back from Krauss’s 
recommendation to consume 8-10% of total calories from 
saturated fat.3 In 2013, the American College of Cardiology 
(ACC), updating the coronary artery disease treatment 
recommendations, issued draconian advice – all “at risk” 
adults (some 45 million healthy people) were told, as a 
precautionary measure, to cut their saturated fat intake down to 
an unprecedented 5% to 6% of calories – approaching a vegan 
diet. This recommendation was justified quoting the DASH and 
OmniHeart studies, in which subjects were fed diets containing 
5% to 6% saturated fat and their LDL-cholesterol levels dropped 
significantly.4,5 This could be interpreted as a positive only if 
Krauss’s work was ignored, along with other trials showing LDL 
wasn’t a meaningful indicator of risk for most people. The ACC 
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also had to ignore the fact that subjects in these two trials saw 
their HDL-cholesterol fall significantly (a bad indicator), that 
there was no improvement in their markers for diabetes, and 
that they lost no weight.
In making its very low saturated fat recommendations, the 
ACC stated it did not consider the impact of its proposed diet on 
diabetes or metabolic syndrome – a truly starling decision, given 
that these conditions are closely linked with atherosclerotic 
cardiovascular disease. Furthermore, the ACC guidelines 
ignored several decades’ worth of large trials, including MRFIT 
and the Women’s Health Initiative, which collectively tested 
more than 61,000 men and women for more than 7 years, and 
which failed to show any benefits of a low-saturated fat diet.  
Instead, the two trials quoted by ACC tested only 590 people 
over 8 weeks. 
Moreover, the ACC continued to extrapolate that dietary 
LDL-lowering had the same biological significance as statin-
induced LDL-lowering. There is no data to support this 
assumption, and the significance of LDL as a biomarker of heart 
attack risk is increasingly doubtful. Unfortunately, the AHA 
2015 (updated 12th August) dietary guidelines have adopted the 
ACC’s 5% to 6% saturated fat recommendation.
By ignoring all the diet and LDL-cholesterol evidence, 
including Krauss’s LDL sub-fractions work, the AHA/ACC 
have preserved LDL as their favoured biomarker, as though the 
last 20 years of science have never happened. The rationale for 
their recommendations remains more political and financial 
than scientific. Indeed, LDL-cholesterol has a following and a 
long history; doctors understand it, governments have entire 
bureaucracies committed to lowering it, academics have 
invested their careers in it, and pharmaceutical companies have 
promoted it.
In a highly controversial move, the ACC 2013 guidelines did 
appear to downgrade LDL-cholesterol slightly by eliminating the 
specific numerical treatment targets which had been in place 
since 1986 (total cholesterol <5.17mmol/L; LDL <3.36 mmol/L; 
HDL >0.91mmol/L; fasting triglycerides 0.45–1.69mmol/L). 
They also promoted “non-HDL-cholesterol” as a new additional 
biomarker. This is calculated by subtracting HDL from total 
cholesterol but, like LDL, its accuracy significantly drops when 
triglycerides are high.
These changes seem to be in the right direction for 
understanding atherosclerosis, but forces separate from science 
may have been at work here too. A cynical observer might point 
to the statin drugs’ patents which have expired in 2013 and that, 
as such, incentives for pharmaceutical companies to continue 
favouring LDL were therefore reduced.
Many diet and disease experts, including Krauss, are 
disappointed by the continued focus on LDL-cholesterol.  When 
in 2006 the AHA guidelines undid all of Krauss’s work on 
saturated fat, he is said to have become disenchanted with the 
dietary guideline process and ramped down his activity within 
the AHA. Indeed, in 2011, he gave up a coveted spot on its 
expert panel since he could not endorse the direction in which it 
was heading.
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